Colchicine Among Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials

Among patients with ACS, colchicine may modestly reduce the incidence of MACE compared with placebo, but this effect is not robust after excluding the study with a higher risk of bias. In addition, no significant benefits were observed for the main individual outcomes of MACE, including all-cause mortality, cardiac mortality, MI, ischemia-driven repeat revascularization and stroke. Yet, colchicine was associated with a higher risk of GI side effects.